SCHEMBL8002873

SCHEMBL8002873

Cn1c(-c2cnccn2)nc(-c2ccc(-c3ncon3)cc2)c1Sc1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.51
KCNH2 Q12809 1/20 0.51
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
PKM P14618 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.35
HSD11B1 P28845 3/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C9 P11712 2/20 0.35
SLC2A1 P11166 2/20 0.34
SLC2A2 P11168 1/20 0.33
GRM5 P41594 1/20 0.32
NR1I2 O75469 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HSD17B10 Q99714 1/20 0.32
CSNK1D P48730 1/20 0.31
CSNK1E P49674 1/20 0.31
POLB P06746 2/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8002533 0.92 FAAH (0.42) FAAHKCNH2NPC1RAB9APKM
SCHEMBL7993038 0.88 FAAH (0.62) FAAHKCNH2NPC1RAB9APKM
SCHEMBL7993039 0.87 FAAH (0.60) FAAHKCNH2NPC1RAB9ACYP3A4
SCHEMBL8005123 0.85 FAAH (0.51) FAAHKCNH2HSD11B1SLC2A1SLC2A2
SCHEMBL1303886 0.85 FAAH (0.48) FAAHKCNH2NPC1RAB9ASLC2A1
SCHEMBL7993050 0.84 FAAH (0.44) FAAHKCNH2NPC1RAB9ASLC2A1
SCHEMBL1303011 0.83 FAAH (0.50) FAAHKCNH2CYP3A4CYP2C9SLC2A1
SCHEMBL8005254 0.82 FAAH (0.55) FAAHKCNH2NPC1RAB9APKM
SCHEMBL12106726 0.81 FAAH (0.47) FAAHKCNH2CYP3A4CYP2C9SLC2A1
SCHEMBL8005124 0.81 FAAH (0.62) FAAHKCNH2NPC1RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
WO-2009152025-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK & CO., INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH FAAH, FAAH2, HNMT FAAH 1/4885KCNH2 1076/4885NPC1 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.